Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2024-07-24 00:00:00 ET · period of report 2024-07-22 · accession 0000950170-24-086061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-07-24 | 2024-07-22 | NTLA | Dulac Edward J III | EVP, CFO | A - Grant | $0.00 | +66.3K | 66.3K | New | $0 |
| D | 2024-07-24 | 2024-07-22 | NTLA | Dulac Edward J III | EVP, CFO | A - Grant | $0.00 | +96.2K | 96.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-22 | A | A | 66,324 | $0.00 | 66,324 | D | — | — | (F1) Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| 2 | Derivative | Stock Option (right to buy) | 2024-07-22 | A | A | 96,219 | $0.00 | 96,219 | D | $25.33 · — to 2034-07-21 | 96,219 Common Stock | (F2) This option was granted on July 22, 2024 with respect to shares of Common Stock, with 33% vesting on July 22, 2025 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. |